25 XP   0   0   10

Protagonist Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Protagonist Therapeutics Inc together

PenkeI guess you are interested in Protagonist Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Protagonist Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Protagonist Therapeutics Inc

I send you an email if I find something interesting about Protagonist Therapeutics Inc.

Quick analysis of Protagonist Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Protagonist Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$5.45
Expected worth in 1 year
$20.11
How sure are you?
43.2%

+ What do you gain per year?

Total Gains per Share
$14.66
Return On Investment
59.4%

For what price can you sell your share?

Current Price per Share
$24.66
Expected price per share
$21.43 - $33.34
How sure are you?
50%

1. Valuation of Protagonist Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$24.66

Intrinsic Value Per Share

$15.49 - $19.40

Total Value Per Share

$20.94 - $24.85

2. Growth of Protagonist Therapeutics Inc (5 min.)




Is Protagonist Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$336.6m$69.1m$218.1m75.9%

How much money is Protagonist Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$19.1m-$30.7m$11.5m60.2%
Net Profit Margin11.4%-1,202.7%--

How much money comes from the company's main activities?

3. Financial Health of Protagonist Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#162 / 1010

Most Revenue
#251 / 1010

Most Profit
#689 / 1010

Most Efficient
#105 / 1010

What can you expect buying and holding a share of Protagonist Therapeutics Inc? (5 min.)

Welcome investor! Protagonist Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Protagonist Therapeutics Inc.

What can you expect buying and holding a share of Protagonist Therapeutics Inc?

First you should know what it really means to hold a share of Protagonist Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Protagonist Therapeutics Inc is $24.66. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Protagonist Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Protagonist Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.45. Based on the TTM, the Book Value Change Per Share is $3.66 per quarter. Based on the YOY, the Book Value Change Per Share is $-3.59 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Protagonist Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.441.8%-0.34-1.4%-0.55-2.2%-0.41-1.7%-0.31-1.2%
Usd Book Value Change Per Share0.341.4%3.6614.9%-3.59-14.6%0.180.7%0.150.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.341.4%3.6614.9%-3.59-14.6%0.180.7%0.150.6%
Usd Price Per Share22.93-22.56-12.73-18.60-13.79-
Price to Earnings Ratio12.96--3.67--6.97--10.34--10.96-
Price-to-Total Gains Ratio66.88-92.85-187.70-71.96-25.99-
Price to Book Ratio4.21-4.79-1.78-5.05-5.22-
Price-to-Total Gains Ratio66.88-92.85-187.70-71.96-25.99-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share24.66
Number of shares40
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share3.660.18
Usd Total Gains Per Share3.660.18
Gains per Quarter (40 shares)146.597.03
Gains per Year (40 shares)586.3628.14
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1058657602818
201173116205646
301759174808474
40234523340113102
50293229200141130
60351835060169158
70410440920197186
80469146780225214
90527752640253242
100586458500281270

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%1.036.00.02.7%1.036.00.02.7%
Book Value Change Per Share4.00.00.0100.0%6.06.00.050.0%10.010.00.050.0%16.018.03.043.2%16.018.03.043.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.037.00.0%0.00.037.00.0%
Total Gains per Share4.00.00.0100.0%6.06.00.050.0%10.010.00.050.0%16.018.03.043.2%16.018.03.043.2%

Fundamentals of Protagonist Therapeutics Inc

About Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Fundamental data was last updated by Penke on 2024-04-12 15:55:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Protagonist Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Protagonist Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Protagonist Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 45.6% means that $0.46 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Protagonist Therapeutics Inc:

  • The MRQ is 45.6%. The company is making a huge profit. +2
  • The TTM is 11.4%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ45.6%TTM11.4%+34.2%
TTM11.4%YOY-1,202.7%+1,214.1%
TTM11.4%5Y-505.8%+517.2%
5Y-505.8%10Y-299.3%-206.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ45.6%-207.2%+252.8%
TTM11.4%-216.8%+228.2%
YOY-1,202.7%-282.3%-920.4%
5Y-505.8%-436.8%-69.0%
10Y-299.3%-597.3%+298.0%
1.1.2. Return on Assets

Shows how efficient Protagonist Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Protagonist Therapeutics Inc to the Biotechnology industry mean.
  • 7.6% Return on Assets means that Protagonist Therapeutics Inc generated $0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Protagonist Therapeutics Inc:

  • The MRQ is 7.6%. Using its assets, the company is efficient in making profit. +1
  • The TTM is -7.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ7.6%TTM-7.0%+14.6%
TTM-7.0%YOY-10.6%+3.6%
TTM-7.0%5Y-9.5%+2.6%
5Y-9.5%10Y-15.7%+6.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.6%-13.3%+20.9%
TTM-7.0%-12.8%+5.8%
YOY-10.6%-11.6%+1.0%
5Y-9.5%-13.8%+4.3%
10Y-15.7%-15.6%-0.1%
1.1.3. Return on Equity

Shows how efficient Protagonist Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Protagonist Therapeutics Inc to the Biotechnology industry mean.
  • 8.1% Return on Equity means Protagonist Therapeutics Inc generated $0.08 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Protagonist Therapeutics Inc:

  • The MRQ is 8.1%. Using its investors money, the company is less efficient in making profit.
  • The TTM is -1.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ8.1%TTM-1.2%+9.4%
TTM-1.2%YOY-8.6%+7.4%
TTM-1.2%5Y-9.1%+7.8%
5Y-9.1%10Y-17.1%+8.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.1%-16.9%+25.0%
TTM-1.2%-16.1%+14.9%
YOY-8.6%-14.9%+6.3%
5Y-9.1%-19.3%+10.2%
10Y-17.1%-20.1%+3.0%

1.2. Operating Efficiency of Protagonist Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Protagonist Therapeutics Inc is operating .

  • Measures how much profit Protagonist Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Protagonist Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 38.4% means the company generated $0.38  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Protagonist Therapeutics Inc:

  • The MRQ is 38.4%. The company is operating very efficient. +2
  • The TTM is 9.6%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ38.4%TTM9.6%+28.8%
TTM9.6%YOY-1,226.7%+1,236.3%
TTM9.6%5Y-510.1%+519.7%
5Y-510.1%10Y-304.4%-205.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ38.4%-298.0%+336.4%
TTM9.6%-238.5%+248.1%
YOY-1,226.7%-288.4%-938.3%
5Y-510.1%-486.2%-23.9%
10Y-304.4%-628.4%+324.0%
1.2.2. Operating Ratio

Measures how efficient Protagonist Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.63 means that the operating costs are $0.63 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Protagonist Therapeutics Inc:

  • The MRQ is 0.630. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.157. The company is very efficient in keeping operating costs low. +2
Trends
Current periodCompared to+/- 
MRQ0.630TTM0.157+0.472
TTM0.157YOY13.012-12.855
TTM0.1575Y5.905-5.748
5Y5.90510Y3.879+2.026
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6303.235-2.605
TTM0.1573.310-3.153
YOY13.0123.838+9.174
5Y5.9055.679+0.226
10Y3.8797.823-3.944

1.3. Liquidity of Protagonist Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Protagonist Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 16.71 means the company has $16.71 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Protagonist Therapeutics Inc:

  • The MRQ is 16.714. The company is very able to pay all its short-term debts. +2
  • The TTM is 12.632. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ16.714TTM12.632+4.082
TTM12.632YOY7.647+4.985
TTM12.6325Y7.741+4.890
5Y7.74110Y6.835+0.907
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ16.7143.863+12.851
TTM12.6324.169+8.463
YOY7.6475.337+2.310
5Y7.7416.122+1.619
10Y6.8356.434+0.401
1.3.2. Quick Ratio

Measures if Protagonist Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Protagonist Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 23.82 means the company can pay off $23.82 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Protagonist Therapeutics Inc:

  • The MRQ is 23.824. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 16.962. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ23.824TTM16.962+6.862
TTM16.962YOY11.421+5.542
TTM16.9625Y11.204+5.759
5Y11.20410Y9.470+1.733
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ23.8243.504+20.320
TTM16.9623.991+12.971
YOY11.4215.371+6.050
5Y11.2046.088+5.116
10Y9.4706.395+3.075

1.4. Solvency of Protagonist Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Protagonist Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Protagonist Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.06 means that Protagonist Therapeutics Inc assets are financed with 5.9% credit (debt) and the remaining percentage (100% - 5.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Protagonist Therapeutics Inc:

  • The MRQ is 0.059. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.081. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.059TTM0.081-0.022
TTM0.081YOY0.893-0.812
TTM0.0815Y0.354-0.273
5Y0.35410Y0.286+0.068
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0590.339-0.280
TTM0.0810.337-0.256
YOY0.8930.271+0.622
5Y0.3540.368-0.014
10Y0.2860.388-0.102
1.4.2. Debt to Equity Ratio

Measures if Protagonist Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Protagonist Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 6.3% means that company has $0.06 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Protagonist Therapeutics Inc:

  • The MRQ is 0.063. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.038. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.063TTM0.038+0.025
TTM0.038YOY0.118-0.080
TTM0.0385Y0.225-0.187
5Y0.22510Y0.207+0.019
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0630.392-0.329
TTM0.0380.403-0.365
YOY0.1180.335-0.217
5Y0.2250.427-0.202
10Y0.2070.461-0.254

2. Market Valuation of Protagonist Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Protagonist Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Protagonist Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of 12.96 means the investor is paying $12.96 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Protagonist Therapeutics Inc:

  • The EOD is 13.937. Based on the earnings, the company is underpriced. +1
  • The MRQ is 12.959. Based on the earnings, the company is underpriced. +1
  • The TTM is -3.669. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD13.937MRQ12.959+0.978
MRQ12.959TTM-3.669+16.628
TTM-3.669YOY-6.968+3.299
TTM-3.6695Y-10.339+6.670
5Y-10.33910Y-10.961+0.622
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD13.937-2.300+16.237
MRQ12.959-2.656+15.615
TTM-3.669-2.718-0.951
YOY-6.968-4.145-2.823
5Y-10.339-6.258-4.081
10Y-10.961-6.315-4.646
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Protagonist Therapeutics Inc:

  • The EOD is 22.488. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 20.911. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is -3.303. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD22.488MRQ20.911+1.578
MRQ20.911TTM-3.303+24.214
TTM-3.303YOY-6.806+3.503
TTM-3.3035Y-6.304+3.001
5Y-6.30410Y-7.803+1.499
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD22.488-2.974+25.462
MRQ20.911-3.306+24.217
TTM-3.303-3.508+0.205
YOY-6.806-5.613-1.193
5Y-6.304-8.378+2.074
10Y-7.803-8.873+1.070
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Protagonist Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.21 means the investor is paying $4.21 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Protagonist Therapeutics Inc:

  • The EOD is 4.526. Based on the equity, the company is fair priced.
  • The MRQ is 4.209. Based on the equity, the company is fair priced.
  • The TTM is 4.787. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD4.526MRQ4.209+0.318
MRQ4.209TTM4.787-0.579
TTM4.787YOY1.781+3.006
TTM4.7875Y5.046-0.259
5Y5.04610Y5.220-0.174
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.5261.914+2.612
MRQ4.2092.116+2.093
TTM4.7872.097+2.690
YOY1.7812.881-1.100
5Y5.0463.550+1.496
10Y5.2203.936+1.284
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Protagonist Therapeutics Inc.

3.1. Institutions holding Protagonist Therapeutics Inc

Institutions are holding 100.45% of the shares of Protagonist Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Bvf Inc9.85822.5845744848196894852.1451
2023-12-31Farallon Capital Management, L.L.C.9.84030.652757344302880005.2879
2023-12-31BlackRock Inc9.51330.003255439023144776.0136
2023-12-31RTW INVESTMENTS, LLC9.12141.90395315514-100000-1.8465
2023-12-31Vanguard Group Inc5.41210.00163153916-74478-2.307
2023-12-31State Street Corporation4.68460.0032729929-1212209-30.75
2023-12-31Johnson & Johnson4.20281.2804244918300
2023-12-31Kynam Capital Management, LP3.44045.0932200487518621810.2393
2023-12-31Adage Capital Partners Gp LLC2.21660.0613129170159170184.5287
2023-12-31Jefferies Financial Group Inc2.18030.19127056143500052.0608
2023-12-31Geode Capital Management, LLC2.14210.0031248284670285.6743
2023-12-31Morgan Stanley - Brokerage Accounts2.04520.00241191837762833177.8149
2023-09-30BRAIDWELL LP1.90330.5847110915011091500
2023-09-30Point72 Asset Management, L.P.1.90160.0539110814011081400
2023-12-31Goldman Sachs Group Inc1.76820.00211030440563237120.5551
2023-12-31Deutsche Bank AG1.56160.01079100128380991165.4346
2023-12-31T. Rowe Price Associates, Inc.1.41350.0025823740-8253-0.992
2023-12-31Dimensional Fund Advisors, Inc.1.40120.0055816537-124737-13.2519
2023-12-31683 Capital Management LLC1.22691.3428715000-17784-2.4269
2023-12-31Northern Trust Corp0.9440.0023550139-12549-2.2302
Total 76.777613.783244742138+6682821+14.9%

3.2. Funds holding Protagonist Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.91790.0033170041600
2024-02-29SPDR® S&P Biotech ETF2.70610.6051576991294601.9037
2024-02-29iShares Russell 2000 ETF2.36790.06721379911-226-0.0164
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.45550.025384821051360.6092
2023-12-31Fidelity Small Cap Index0.97610.051356883177801.3867
2024-01-31Fidelity Select Biotechnology0.72740.229842391300
2024-01-31BlackRock Health Sciences Term Trust0.72370.559942172500
2024-02-29iShares Biotechnology ETF0.70950.1651413440-1860-0.4479
2024-01-31Candriam Eqs L Biotech C USD Cap0.7070.6274412000-125000-23.2775
2024-01-31BlackRock Health Sciences Opps Inv A0.69320.121640393500
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.59870.025434889358001.6905
2024-01-31Fidelity Extended Market Index0.55150.022432140831941.0037
2024-02-29iShares Russell 2000 Growth ETF0.5410.0844315239-367-0.1163
2024-02-29Schwab US Small-Cap ETF™0.46670.050427199300
2024-01-31DFA US Micro Cap I0.36560.078321305900
2024-02-29State St Russell Sm Cap® Indx SL Cl I0.36150.067821068000
2024-01-31DFA US Small Cap I0.35810.035420869000
2024-02-29Vanguard Russell 2000 ETF0.35650.0662207770163768.5562
2024-02-01iShares Russell 2000 Value ETF0.33930.04771977212500.1266
2023-12-31NT R2000 Index Fund - NL0.28260.052116468311200.6848
Total 18.20582.98610609508-58337-0.5%

3.3. Insider Transactions

Insiders are holding 1.75% of the shares of Protagonist Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-04-01Dinesh V Ph D PatelSELL2500028.31
2024-03-01Asif AliSELL1424832.24
2024-03-01Dinesh V Ph D PatelSELL3000031.62
2024-03-01William D WaddillSELL1297531.34
2024-01-09Suneel GuptaSELL500025

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Protagonist Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.3433.665-91%-3.590+1147%0.176+95%0.147+133%
Book Value Per Share--5.4484.827+13%1.187+359%3.164+72%2.196+148%
Current Ratio--16.71412.632+32%7.647+119%7.741+116%6.835+145%
Debt To Asset Ratio--0.0590.081-27%0.893-93%0.354-83%0.286-79%
Debt To Equity Ratio--0.0630.038+65%0.118-46%0.225-72%0.207-69%
Dividend Per Share----0%-0%-0%-0%
Eps--0.442-0.343+178%-0.547+224%-0.409+192%-0.307+169%
Free Cash Flow Per Share--0.274-0.306+212%-0.467+270%-0.347+227%-0.234+185%
Free Cash Flow To Equity Per Share--0.2830.423-33%-0.387+237%0.178+59%0.161+76%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--19.398--------
Intrinsic Value_10Y_min--15.495--------
Intrinsic Value_1Y_max---1.135--------
Intrinsic Value_1Y_min---1.117--------
Intrinsic Value_3Y_max---1.065--------
Intrinsic Value_3Y_min---1.064--------
Intrinsic Value_5Y_max--1.835--------
Intrinsic Value_5Y_min--1.501--------
Market Cap1437061500.000+1%1416986980.6501338509558.993+6%741986437.500+91%1088796661.799+30%805951736.107+76%
Net Profit Margin--0.4560.114+300%-12.027+2740%-5.058+1210%-2.993+757%
Operating Margin--0.3840.096+300%-12.267+3293%-5.101+1428%-3.044+892%
Operating Ratio--0.6300.157+300%13.012-95%5.905-89%3.879-84%
Pb Ratio4.526+7%4.2094.787-12%1.781+136%5.046-17%5.220-19%
Pe Ratio13.937+7%12.959-3.669+128%-6.968+154%-10.339+180%-10.961+185%
Price Per Share24.660+7%22.93022.558+2%12.733+80%18.602+23%13.786+66%
Price To Free Cash Flow Ratio22.488+7%20.911-3.303+116%-6.806+133%-6.304+130%-7.803+137%
Price To Total Gains Ratio71.929+7%66.88392.852-28%187.696-64%71.961-7%25.988+157%
Quick Ratio--23.82416.962+40%11.421+109%11.204+113%9.470+152%
Return On Assets--0.076-0.070+191%-0.106+239%-0.095+225%-0.157+306%
Return On Equity--0.081-0.012+115%-0.086+206%-0.091+212%-0.171+311%
Total Gains Per Share--0.3433.665-91%-3.590+1147%0.176+95%0.147+133%
Usd Book Value--336677000.000287265250.000+17%69154250.000+387%185597500.000+81%128604054.054+162%
Usd Book Value Change Per Share--0.3433.665-91%-3.590+1147%0.176+95%0.147+133%
Usd Book Value Per Share--5.4484.827+13%1.187+359%3.164+72%2.196+148%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.442-0.343+178%-0.547+224%-0.409+192%-0.307+169%
Usd Free Cash Flow--16941000.000-17711250.000+205%-27233000.000+261%-20209600.000+219%-13637729.730+181%
Usd Free Cash Flow Per Share--0.274-0.306+212%-0.467+270%-0.347+227%-0.234+185%
Usd Free Cash Flow To Equity Per Share--0.2830.423-33%-0.387+237%0.178+59%0.161+76%
Usd Market Cap1437061500.000+1%1416986980.6501338509558.993+6%741986437.500+91%1088796661.799+30%805951736.107+76%
Usd Price Per Share24.660+7%22.93022.558+2%12.733+80%18.602+23%13.786+66%
Usd Profit--27335000.000-19164750.000+170%-30706500.000+212%-23418650.000+186%-16415162.162+160%
Usd Revenue--60000000.00015000000.000+300%6645250.000+803%7139850.000+740%5237432.432+1046%
Usd Total Gains Per Share--0.3433.665-91%-3.590+1147%0.176+95%0.147+133%
 EOD+4 -4MRQTTM+21 -12YOY+28 -55Y+29 -410Y+30 -3

4.2. Fundamental Score

Let's check the fundamental score of Protagonist Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1513.937
Price to Book Ratio (EOD)Between0-14.526
Net Profit Margin (MRQ)Greater than00.456
Operating Margin (MRQ)Greater than00.384
Quick Ratio (MRQ)Greater than123.824
Current Ratio (MRQ)Greater than116.714
Debt to Asset Ratio (MRQ)Less than10.059
Debt to Equity Ratio (MRQ)Less than10.063
Return on Equity (MRQ)Greater than0.150.081
Return on Assets (MRQ)Greater than0.050.076
Total8/10 (80.0%)

4.3. Technical Score

Let's check the technical score of Protagonist Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5034.200
Ma 20Greater thanMa 5027.082
Ma 50Greater thanMa 10028.351
Ma 100Greater thanMa 20025.926
OpenGreater thanClose25.130
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Income before Tax  -34,194469-33,725-4,735-38,4604,355-34,10561,44027,335
Net Income  -31,285-144-31,429-7,031-38,4604,355-34,10561,44027,335
Gross Profit  -256-576-83211-821-6-82759,99559,168
EBIT  -37,356503-36,853-5,501-42,3543,201-39,15362,20223,049
EBITDA  -36,516495-36,021-5,512-41,5333,207-38,32662,20723,881
Operating Income  -36,516495-36,021-6,333-42,3544,028-38,32661,37523,049
Net Income from Continuing Operations  -34,194469-33,725-4,735-38,4604,355-34,10561,44027,335



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets357,951
Total Liabilities21,274
Total Stockholder Equity336,677
 As reported
Total Liabilities 21,274
Total Stockholder Equity+ 336,677
Total Assets = 357,951

Assets

Total Assets357,951
Total Current Assets355,577
Long-term Assets2,374
Total Current Assets
Cash And Cash Equivalents 186,727
Short-term Investments 154,890
Net Receivables 10,332
Other Current Assets 3,628
Total Current Assets  (as reported)355,577
Total Current Assets  (calculated)355,577
+/-0
Long-term Assets
Property Plant Equipment 2,149
Long-term Assets Other 225
Long-term Assets  (as reported)2,374
Long-term Assets  (calculated)2,374
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities21,274
Long-term Liabilities221
Total Stockholder Equity336,677
Total Current Liabilities
Short-term Debt 1,141
Accounts payable 772
Other Current Liabilities 19,358
Total Current Liabilities  (as reported)21,274
Total Current Liabilities  (calculated)21,271
+/- 3
Long-term Liabilities
Long-term Liabilities  (as reported)221
Long-term Liabilities  (calculated)0
+/- 221
Total Stockholder Equity
Common Stock1
Retained Earnings -615,710
Accumulated Other Comprehensive Income -105
Other Stockholders Equity 952,491
Total Stockholder Equity (as reported)336,677
Total Stockholder Equity (calculated)336,677
+/-0
Other
Capital Stock1
Cash and Short Term Investments 341,617
Common Stock Shares Outstanding 61,796
Current Deferred Revenue3
Liabilities and Stockholders Equity 357,951
Net Debt -185,586
Net Invested Capital 336,677
Net Working Capital 334,303
Property Plant and Equipment Gross 8,383
Short Long Term Debt Total 1,141



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-31
> Total Assets 
10,328
0
0
0
14,845
31,856
24,516
102,843
93,990
82,673
70,479
110,415
163,734
149,239
137,473
148,856
139,472
132,248
148,105
154,627
154,917
134,901
224,980
217,320
324,468
298,072
404,232
373,175
347,695
348,296
310,512
282,174
247,928
239,858
320,466
330,016
357,951
357,951330,016320,466239,858247,928282,174310,512348,296347,695373,175404,232298,072324,468217,320224,980134,901154,917154,627148,105132,248139,472148,856137,473149,239163,734110,41570,47982,67393,990102,84324,51631,85614,84500010,328
   > Total Current Assets 
9,913
9,324
0
0
14,206
30,937
22,417
102,245
83,244
67,548
69,126
97,704
150,947
142,231
136,111
147,502
137,503
122,995
137,320
144,023
145,311
125,986
217,466
204,151
315,606
285,508
371,818
327,687
340,736
341,522
304,302
276,617
237,355
235,736
316,941
324,881
355,577
355,577324,881316,941235,736237,355276,617304,302341,522340,736327,687371,818285,508315,606204,151217,466125,986145,311144,023137,320122,995137,503147,502136,111142,231150,94797,70469,12667,54883,244102,24522,41730,93714,206009,3249,913
       Cash And Cash Equivalents 
9,324
-9,324
0
0
4,055
28,629
13,768
96,024
21,084
9,517
10,365
50,395
106,029
69,577
63,864
87,427
82,233
70,077
71,143
50,195
33,006
60,215
146,242
83,625
117,358
83,000
192,412
120,542
123,665
98,477
120,237
152,816
125,744
127,686
235,382
230,527
186,727
186,727230,527235,382127,686125,744152,816120,23798,477123,665120,542192,41283,000117,35883,625146,24260,21533,00650,19571,14370,07782,23387,42763,86469,577106,02950,39510,3659,51721,08496,02413,76828,6294,05500-9,3249,324
       Short-term Investments 
10
18,648
0
0
7,868
393
6,408
2,499
56,515
53,731
54,127
43,191
37,972
65,383
61,303
51,090
46,620
42,469
54,958
87,497
100,011
57,298
62,423
110,349
188,451
190,476
161,868
193,759
203,235
206,812
171,653
114,621
111,611
103,073
78,019
90,224
154,890
154,89090,22478,019103,073111,611114,621171,653206,812203,235193,759161,868190,476188,451110,34962,42357,298100,01187,49754,95842,46946,62051,09061,30365,38337,97243,19154,12753,73156,5152,4996,4083937,8680018,64810
       Net Receivables 
523
0
0
0
715
1,290
1,744
1,944
2,241
2,480
2,881
1,405
3,163
4,640
7,975
5,741
6,016
6,937
6,310
2,118
6,755
3,747
3,273
3,324
3,510
5,819
9,855
4,509
4,358
28,028
3,363
620
52
51
50
65
10,332
10,332655051526203,36328,0284,3584,5099,8555,8193,5103,3243,2733,7476,7552,1186,3106,9376,0165,7417,9754,6403,1631,4052,8812,4802,2411,9441,7441,290715000523
       Other Current Assets 
56
0
0
0
305
373
487
1,768
906
1,810
1,743
2,703
1,071
2,621
2,959
3,234
495
3,502
4,899
4,203
744
4,716
5,518
6,843
311
6,213
7,683
8,877
975
476
9,049
9,180
42
4,977
3,540
4,130
3,628
3,6284,1303,5404,977429,1809,0494769758,8777,6836,2133116,8435,5184,7167444,2034,8993,5024953,2342,9592,6211,0712,7031,7431,8109061,76848737330500056
   > Long-term Assets 
0
0
0
0
639
919
2,099
598
10,746
15,125
1,353
12,711
12,787
7,008
1,362
1,354
1,969
9,253
10,785
10,604
9,606
8,915
7,514
13,169
8,862
12,564
32,414
45,488
6,959
6,774
6,210
5,557
10,573
4,122
3,525
5,135
2,374
2,3745,1353,5254,12210,5735,5576,2106,7746,95945,48832,41412,5648,86213,1697,5148,9159,60610,60410,7859,2531,9691,3541,3627,00812,78712,7111,35315,12510,7465982,0999196390000
       Property Plant Equipment 
415
0
0
0
609
753
599
564
562
641
903
945
879
1,001
912
904
861
8,325
8,231
8,029
7,723
7,383
7,064
6,694
6,412
6,085
6,067
7,094
6,734
6,549
5,985
5,332
4,626
3,897
3,300
2,925
2,149
2,1492,9253,3003,8974,6265,3325,9856,5496,7347,0946,0676,0856,4126,6947,0647,3837,7238,0298,2318,3258619049121,001879945903641562564599753609000415
       Long Term Investments 
10,150
0
0
0
10,150
10,150
0
0
10,150
14,000
0
11,316
11,458
5,557
0
0
0
0
0
0
0
0
0
6,025
2,000
6,254
26,122
38,169
0
0
0
0
0
0
0
1,985
0
01,985000000038,16926,1226,2542,0006,0250000000005,55711,45811,316014,00010,1500010,15010,15000010,150
       Long-term Assets Other 
0
0
0
0
30
166
1,500
34
34
484
450
450
450
450
450
450
450
450
450
450
450
450
450
450
450
225
225
225
225
225
225
225
5,722
225
225
225
225
2252252252255,72222522522522522522522545045045045045045045045045045045045045045045048434341,500166300000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
658
478
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000004786580000000000000000
> Total Liabilities 
2,373
0
0
0
5,249
5,475
4,110
5,349
6,435
7,779
9,449
52,579
43,102
34,618
29,811
24,898
26,957
31,423
63,789
59,269
74,953
72,235
57,495
47,730
44,862
38,738
46,785
43,515
47,674
46,518
42,534
38,558
784,683
23,691
26,398
27,867
21,274
21,27427,86726,39823,691784,68338,55842,53446,51847,67443,51546,78538,73844,86247,73057,49572,23574,95359,26963,78931,42326,95724,89829,81134,61843,10252,5799,4497,7796,4355,3494,1105,4755,2490002,373
   > Total Current Liabilities 
1,350
0
0
0
3,126
4,470
4,110
5,349
6,435
7,779
9,366
52,247
42,555
33,924
29,018
24,101
26,158
24,499
33,323
30,776
35,406
36,372
35,360
38,563
40,241
34,515
42,973
39,156
44,016
43,456
40,088
36,754
31,179
23,229
26,398
27,867
21,274
21,27427,86726,39823,22931,17936,75440,08843,45644,01639,15642,97334,51540,24138,56335,36036,37235,40630,77633,32324,49926,15824,10129,01833,92442,55552,2479,3667,7796,4355,3494,1104,4703,1260001,350
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,061
1,120
1,164
1,209
1,256
1,306
1,355
1,406
1,459
1,512
1,567
2,027
2,200
2,275
2,352
2,433
2,515
2,599
2,446
1,803
1,141
1,1411,8032,4462,5992,5152,4332,3522,2752,2002,0271,5671,5121,4591,4061,3551,3061,2561,2091,1641,1201,0610000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,120
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000001,12000000000000000000
       Accounts payable 
349
0
0
0
1,247
1,890
1,441
2,335
1,163
1,132
2,639
2,267
1,257
1,307
2,278
4,871
5,711
6,454
2,787
1,583
2,790
3,704
2,855
2,797
3,075
2,732
7,905
706
1,600
7,159
1,412
4,715
3,640
4,021
4,573
1,252
772
7721,2524,5734,0213,6404,7151,4127,1591,6007067,9052,7323,0752,7972,8553,7042,7901,5832,7876,4545,7114,8712,2781,3071,2572,2672,6391,1321,1632,3351,4411,8901,247000349
       Other Current Liabilities 
1,001
0
0
0
1,879
2,580
2,669
3,014
5,272
6,647
6,727
8,241
9,546
10,358
13,262
10,496
11,163
8,713
10,845
10,486
-10,170
11,616
12,917
15,518
21,230
17,680
20,096
33,061
38,615
32,874
36,244
29,574
24,955
16,587
19,369
24,809
19,358
19,35824,80919,36916,58724,95529,57436,24432,87438,61533,06120,09617,68021,23015,51812,91711,616-10,17010,48610,8458,71311,16310,49613,26210,3589,5468,2416,7276,6475,2723,0142,6692,5801,8790001,001
   > Long-term Liabilities 
0
0
0
0
2,123
1,005
0
0
0
0
83
332
547
694
793
797
799
6,924
30,466
28,493
39,547
35,863
22,135
9,167
4,621
4,223
3,812
4,359
3,658
3,062
2,446
1,804
784,683
462
0
0
221
22100462784,6831,8042,4463,0623,6584,3593,8124,2234,6219,16722,13535,86339,54728,49330,4666,9247997977936945473328300001,0052,1230000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,794
9,832
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000009,8329,79400000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1,061
6,924
6,616
6,293
5,961
5,616
5,259
4,885
4,500
4,102
3,691
4,238
3,658
3,062
2,446
1,804
1,141
462
0
0
0
0004621,1411,8042,4463,0623,6584,2383,6914,1024,5004,8855,2595,6165,9616,2936,6166,924-1,0610000000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
658
478
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000004786580000000000000000
       Warrants
0
0
0
0
0
0
66,610
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000066,610000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,924
30,466
28,493
29,753
26,031
92
170
4,621
4,223
121
4,359
3,658
3,062
2,446
1,804
1,141
462
0
0
0
0004621,1411,8042,4463,0623,6584,3591214,2234,6211709226,03129,75328,49330,4666,92400000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
83
332
547
694
793
797
799
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000799797793694547332830000000000
> Total Stockholder Equity
7,955
8,978
0
0
9,596
26,381
20,406
97,494
-64,593
74,894
61,030
-98,498
-101,550
114,621
107,662
123,958
-140,474
100,825
84,316
95,358
-217,661
62,666
167,485
169,590
-283,811
259,334
357,447
329,660
-409,362
301,778
267,978
243,616
-536,755
-570,480
294,068
-643,045
336,677
336,677-643,045294,068-570,480-536,755243,616267,978301,778-409,362329,660357,447259,334-283,811169,590167,48562,666-217,66195,35884,316100,825-140,474123,958107,662114,621-101,550-98,49861,03074,894-64,59397,49420,40626,3819,596008,9787,955
   Common Stock
0
0
0
0
-929
95
101
-102,819
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
11110000000000000000000000000-102,81910195-9290000
   Retained Earnings Total Equity00-608,940-570,480-536,755-502,561-471,329-430,292-409,362-372,455-338,651-307,809-283,811-264,925-257,162-237,741-217,661-200,160-183,751-154,577-140,474-126,609-117,874-109,211-101,550-98,500-93,700-78,694-64,593-53,345-46,261000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-102
-95
-101
-24
-245
-22
3
100
-6
-72
-86
-103
-233
-189
-167
-154
-221
107
-208
-88
28
-33
-59
-204
-299
-472
-720
-480
-359
-122
-198
-170
-105
-105-170-198-122-359-480-720-472-299-204-59-3328-88-208107-221-154-167-189-233-103-86-72-61003-22-245-24-101-95-1020000
   Capital Surplus 
0
0
0
0
0
0
158
150,863
152,393
153,610
154,700
156,234
222,188
223,904
225,622
250,670
253,222
255,591
268,234
295,672
297,846
300,300
424,855
434,603
563,389
567,176
696,157
702,319
709,682
732,542
740,027
746,657
752,722
786,768
903,205
0
0
00903,205786,768752,722746,657740,027732,542709,682702,319696,157567,176563,389434,603424,855300,300297,846295,672268,234255,591253,222250,670225,622223,904222,188156,234154,700153,610152,393150,863158000000
   Treasury Stock0000000000000000000000000000000000000
   Other Stockholders Equity 
-100
-12,621
0
0
1,047
182
57
150,839
245
153,610
154,700
-100
6
223,904
225,622
250,670
233
255,591
268,234
295,672
221
300,300
424,855
434,603
-28
567,176
696,157
702,319
299
732,542
740,027
746,657
359
121
903,205
169
952,491
952,491169903,205121359746,657740,027732,542299702,319696,157567,176-28434,603424,855300,300221295,672268,234255,591233250,670225,622223,9046-100154,700153,610245150,839571821,04700-12,621-100



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue60,000
Cost of Revenue-3,312
Gross Profit56,68856,688
 
Operating Income (+$)
Gross Profit56,688
Operating Expense-153,652
Operating Income-93,652-96,964
 
Operating Expense (+$)
Research Development120,161
Selling General Administrative33,491
Selling And Marketing Expenses0
Operating Expense153,652153,652
 
Net Interest Income (+$)
Interest Income12,907
Interest Expense-0
Other Finance Cost-0
Net Interest Income12,907
 
Pretax Income (+$)
Operating Income-93,652
Net Interest Income12,907
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-78,955-93,451
EBIT - interestExpense = -93,652
-93,853
-78,955
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-93,652-78,955
Earnings Before Interest and Taxes (EBITDA)-90,340
 
After tax Income (+$)
Income Before Tax-78,955
Tax Provision-0
Net Income From Continuing Ops-140,484-78,955
Net Income-78,955
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses153,652
Total Other Income/Expenses Net-201-12,907
 

Technical Analysis of Protagonist Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Protagonist Therapeutics Inc. The general trend of Protagonist Therapeutics Inc is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Protagonist Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Protagonist Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 29.21 < 33.34.

The bearish price targets are: 23.88 > 23.17 > 21.43.

Tweet this
Protagonist Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Protagonist Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Protagonist Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Protagonist Therapeutics Inc. The current macd is -0.78130431.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Protagonist Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Protagonist Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Protagonist Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Protagonist Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartProtagonist Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Protagonist Therapeutics Inc. The current adx is 15.48.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Protagonist Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Protagonist Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Protagonist Therapeutics Inc. The current sar is 27.78.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Protagonist Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Protagonist Therapeutics Inc. The current rsi is 34.20. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Protagonist Therapeutics Inc Daily Relative Strength Index (RSI) ChartProtagonist Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Protagonist Therapeutics Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Protagonist Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Protagonist Therapeutics Inc Daily Stochastic Oscillator ChartProtagonist Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Protagonist Therapeutics Inc. The current cci is -150.3869598.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Protagonist Therapeutics Inc Daily Commodity Channel Index (CCI) ChartProtagonist Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Protagonist Therapeutics Inc. The current cmo is -39.33358631.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Protagonist Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartProtagonist Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Protagonist Therapeutics Inc. The current willr is -96.80851064.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Protagonist Therapeutics Inc Daily Williams %R ChartProtagonist Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Protagonist Therapeutics Inc. The current atr is 1.14295495.

Protagonist Therapeutics Inc Daily Average True Range (ATR) ChartProtagonist Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Protagonist Therapeutics Inc. The current obv is 55,986,874.

Protagonist Therapeutics Inc Daily On-Balance Volume (OBV) ChartProtagonist Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Protagonist Therapeutics Inc. The current mfi is 27.21.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Protagonist Therapeutics Inc Daily Money Flow Index (MFI) ChartProtagonist Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Protagonist Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-06ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Protagonist Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Protagonist Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5034.200
Ma 20Greater thanMa 5027.082
Ma 50Greater thanMa 10028.351
Ma 100Greater thanMa 20025.926
OpenGreater thanClose25.130
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Protagonist Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Protagonist Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Protagonist Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Protagonist Therapeutics Inc

I send you an email if I find something interesting about Protagonist Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Protagonist Therapeutics Inc.

Receive notifications about Protagonist Therapeutics Inc in your mailbox!